FDA will reconsider decision barring copycat versions of Lilly weight loss drug
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage
The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...
Trump says national abortion ban ‘off the table’
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump hedges on abortion banFormer ...
Unemployed to be given weight-loss jabs to ‘get them back to work’
Unemployed people will be given weight-loss jabs under Government plans to get them back to work.Wes Streeting, the Health ...
Unemployed to be given weight-loss jab to help them back into work
The new trial aims to gather evidence of the effects of the drug tirzepatide – sold by pharmaceutical company Lily under ...
Hims & Hers Stock Soars 7% as FDA Reconsiders Limits on Compounded Weight-Loss Drugs
Hims & Hers Health saw its shares surge by 7% today after the FDA announced that it would reconsider its decision to limit ...
FDA, facing pressure, to review position on Zepbound, Mounjaro shortage
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling ...
Hims & Hers Health Stock Is Popping Monday: What's Behind The Move?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would ...
Becker's Hospital Review8 小时
FDA to reconsider decision barring sale of compounded Mounjaro: 5 things to know
The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.
BofA上调Hims and Hers目标价，因FDA药品更新
BofA Securities调整了对Hims and Hers (NYSE:HIMS)的展望，将目标价从20.00美元上调至23.00美元，并维持买入评级。这一调整是基于美国食品和药物管理局（FDA）最近宣布重新评估曾列入短缺清单的tirzepatide药物的可用性。 FDA在周五的一份法庭文件中表示，将重新考虑早前将tirzepatide从短缺清单中移除的决定。该机构还指出，在审查该活性成分的 ...
Pulse8 小时
Government enters ‘strategic collaboration’ with tirzepatide obesity drug maker
The UK Government has signed a collaboration agreement with Lilly, the pharmaceutical giant behind weight loss medication ...